# WiFi-Vision-Pro Roadmap to Unicorn

## üéØ Vision

Transform WiFi signals into medical-grade through-wall imaging, providing $1K remote healthcare solution to 2.5 billion underserved people globally.

**Target:** $5B-$10B valuation by Year 5-7

---

## üìä Current Status (as of Oct 2025)

**Stage:** üü° **Prototype ‚Üí MVP Transition**

| Component | Completeness | Status |
|-----------|--------------|--------|
| Documentation | 95% | ‚úÖ World-class |
| Layer 0 (Computer Vision) | 75% | ‚úÖ Production-ready |
| Layer 1 (WiFi CSI) | 40% | üü° Simulated, needs hardware |
| Layer 2 (Sensor Fusion) | 50% | üü° Architecture ready, no training |
| Layer 3 (Medical App) | 45% | üü° Framework ready, no FDA |
| Testing | 10% | üî¥ Critical gap |
| Hardware Validation | 0% | üî¥ BLOCKER |

**Overall Completeness:** ~45-50%

---

## üõ£Ô∏è Phase 0: MVP Foundation (Now - 3 months)

**Goal:** De-risk core technology and validate feasibility

**Budget:** $50K (bootstrap / pre-seed)

### Milestones

#### M0.1: ESP32-S3 Hardware Validation ‚è∞ 2 weeks (BLOCKER)
**Owner:** Technical lead
**Priority:** üî¥ P0

- [ ] Acquire 3x ESP32-S3 devices ($30)
- [ ] Flash ESP-CSI firmware
- [ ] Validate CSI extraction (1000 Hz, 52 subcarriers)
- [ ] Test through-wall penetration (drywall, 30cm)
- [ ] Measure SNR (target >10 dB)

**Success criteria:**
- Real CSI data collected (10+ minutes)
- Person detection through wall demonstrated
- SNR sufficient for vital signs

**Exit criteria if failed:**
- PIVOT to camera-only medical device
- Update architecture to Layer 0 + Layer 3 only

**[GitHub Issue #1](https://github.com/Yatrogenesis/WiFi-Vision-Pro/issues/1)**

---

#### M0.2: Demo Video Creation ‚è∞ 1 week
**Owner:** Marketing / Founder
**Priority:** üü° P1

- [ ] Record 60-second demo video
- [ ] Show split-screen (camera + WiFi)
- [ ] Demonstrate through-wall detection
- [ ] Professional editing and voiceover
- [ ] Upload to YouTube, embed in README

**Success criteria:**
- 1,000+ views in first week
- Used in fundraising deck
- Posted on HackerNews/Twitter

**[GitHub Issue #2](https://github.com/Yatrogenesis/WiFi-Vision-Pro/issues/2)**

---

#### M0.3: Testing Infrastructure ‚è∞ 1 week
**Owner:** Technical lead
**Priority:** üü° P1

- [ ] Setup pytest framework
- [ ] Unit tests for all layers (80%+ coverage)
- [ ] Integration tests (camera + WiFi pipeline)
- [ ] CI/CD with GitHub Actions
- [ ] Performance benchmarks

**Success criteria:**
- All tests passing
- <1% regression rate
- CI runs on every PR

**[GitHub Issue #3](https://github.com/Yatrogenesis/WiFi-Vision-Pro/issues/3)**

---

#### M0.4: Initial Dataset Collection ‚è∞ 4 weeks (parallel)
**Owner:** Data team / Interns
**Priority:** üü° P1

- [ ] Collect 20 hours real CSI data
- [ ] 5 scenarios (resting, walking, multi-person, etc)
- [ ] Ground truth: pulse ox + chest belt
- [ ] Video synchronization
- [ ] Data cleaning and annotation

**Success criteria:**
- 20+ hours usable data
- Ground truth accuracy >95%
- Dataset structure documented

**[GitHub Issue #4](https://github.com/Yatrogenesis/WiFi-Vision-Pro/issues/4)**

---

### Phase 0 Outcomes

**Technical:**
- ‚úÖ Hardware validated OR pivot decision made
- ‚úÖ 20 hours real dataset
- ‚úÖ Testing infrastructure in place
- ‚úÖ Demo video for marketing

**Business:**
- ‚úÖ Clarity on technical feasibility
- ‚úÖ Materials for Pre-Seed fundraising
- ‚úÖ Decision: Go/No-Go on WiFi CSI

**Valuation:** $5M-$10M (post Phase 0)

---

## üå± Phase 1: Pre-Seed ($100K-$250K, 3-6 months)

**Goal:** Prove medical-grade accuracy and prepare for Seed round

**Sources:**
- SBIR/STTR grants ($150K)
- Angel investors ($50-100K)
- Accelerators (MedTech Innovator, Techstars)

### Milestones

#### M1.1: Dataset Expansion ‚è∞ 8 weeks
- [ ] 100+ hours CSI data across diverse scenarios
- [ ] 20+ subjects (age 18-80)
- [ ] Multi-room configurations
- [ ] Different wall materials (drywall, brick, concrete)
- [ ] Edge cases (metal obstacles, interference)

**Deliverable:** Public dataset (competitive advantage)

---

#### M1.2: Sensor Fusion Model Training ‚è∞ 6 weeks
- [ ] Train multi-modal fusion network (camera + WiFi)
- [ ] Hyperparameter optimization
- [ ] Cross-validation (5-fold)
- [ ] Accuracy >85% on held-out test set
- [ ] Model compression for edge deployment

**Deliverable:** Trained PyTorch model (.pth checkpoint)

---

#### M1.3: Medical Accuracy Benchmarking ‚è∞ 4 weeks
- [ ] Compare vital signs vs clinical devices
  - Heart rate: <5 BPM error (vs pulse oximeter)
  - Respiratory rate: <2 breaths/min error (vs chest belt)
- [ ] Fall detection: >90% sensitivity, >90% specificity
- [ ] Bland-Altman plots for clinical validation
- [ ] Statistical analysis (ICC >0.9)

**Deliverable:** Technical report with clinical metrics

---

#### M1.4: University Partnership ‚è∞ 2 months
- [ ] Approach MIT Media Lab, Stanford BioX, or similar
- [ ] Propose collaborative research project
- [ ] Co-author academic paper
- [ ] Use university facilities for testing

**Deliverable:** LOI (Letter of Intent) from university

---

### Phase 1 Outcomes

**Technical:**
- ‚úÖ 100+ hours dataset
- ‚úÖ Trained fusion model (medical-grade accuracy)
- ‚úÖ Peer-reviewed paper submitted (IEEE/ACM)

**Business:**
- ‚úÖ University partnership (credibility)
- ‚úÖ Grant funding secured
- ‚úÖ Materials for Seed deck

**Valuation:** $15M-$25M (pre-Seed round)

---

## üí∞ Phase 2: Seed Round ($3M-$5M, 6-12 months)

**Goal:** FDA submission preparation and commercial pilot

**Lead investors:** Healthcare VCs, Medical device funds

### Milestones

#### M2.1: Regulatory Strategy ‚è∞ 3 months
- [ ] Hire regulatory consultant ($150K/year)
- [ ] Pre-submission meeting with FDA
- [ ] Define Class II 510(k) pathway
- [ ] Identify predicate devices
- [ ] Design controls documentation
- [ ] ISO 13485 QMS setup

**Deliverable:** FDA Pre-Sub feedback, regulatory roadmap

---

#### M2.2: Clinical Study Protocol ‚è∞ 3 months
- [ ] IRB approval (Institutional Review Board)
- [ ] Recruit clinical site (hospital/clinic)
- [ ] Design protocol: N=70 subjects
  - 50 healthy volunteers
  - 20 patients with respiratory conditions
- [ ] Statistical analysis plan (power calculation)
- [ ] Informed consent documents

**Deliverable:** IRB-approved protocol

---

#### M2.3: Clinical Study Execution ‚è∞ 9 months
- [ ] Recruit 70 subjects
- [ ] 8 hours monitoring per subject
- [ ] Comparator devices:
  - Capnography (respiratory rate)
  - Pulse oximetry (heart rate)
  - Polysomnography (sleep apnea)
- [ ] Data collection and monitoring
- [ ] Adverse event reporting (if any)

**Deliverable:** Complete dataset, no safety issues

---

#### M2.4: Manufacturing Partnership ‚è∞ 6 months (parallel)
- [ ] Design custom WiFi nodes (PCB)
- [ ] Partner with ESP32 manufacturer (Espressif?)
- [ ] Prototype 100 units
- [ ] Reliability testing (temperature, humidity, drop)
- [ ] CE/FCC certification

**Deliverable:** 100 production-quality units

---

#### M2.5: SaaS Platform Development ‚è∞ 9 months (parallel)
- [ ] Cloud infrastructure (AWS/GCP)
- [ ] Multi-tenant SaaS architecture
- [ ] HIPAA-compliant data storage
- [ ] Telemedicine integration (Zoom Health, Doxy.me)
- [ ] Dashboard for clinicians
- [ ] Mobile app (iOS/Android)

**Deliverable:** Beta SaaS platform (10 pilot customers)

---

### Phase 2 Outcomes

**Technical:**
- ‚úÖ Clinical study complete (N=70)
- ‚úÖ Manufacturing partnership established
- ‚úÖ SaaS platform in beta

**Regulatory:**
- ‚úÖ FDA Pre-Sub complete
- ‚úÖ 510(k) submission prepared (90%)
- ‚úÖ ISO 13485 QMS implemented

**Business:**
- ‚úÖ 10 pilot customers (hospitals/clinics)
- ‚úÖ Letters of intent for $500K ARR
- ‚úÖ Series A traction demonstrated

**Valuation:** $50M-$100M (post-Seed, pre-FDA)

---

## üè• Phase 3: FDA Clearance (12-18 months)

**Goal:** Achieve FDA 510(k) clearance and commercial launch

**Funding:** Series A ($15M-$25M)

### Milestones

#### M3.1: 510(k) Submission ‚è∞ 3 months
- [ ] Compile submission dossier:
  - Device description
  - Indications for use
  - Clinical study results
  - Statistical analysis
  - Substantial equivalence comparison
  - Risk analysis (ISO 14971)
  - Software validation
- [ ] Submit to FDA (CDRH)
- [ ] Pay user fee ($12K-$20K)

**Deliverable:** 510(k) submitted

---

#### M3.2: FDA Review Process ‚è∞ 3-6 months
- [ ] Respond to FDA questions (RTA - Refuse to Accept)
- [ ] Provide additional data if requested
- [ ] Deficiency letter response (if any)
- [ ] Final clearance decision

**Success criteria:**
- ‚úÖ FDA 510(k) clearance granted
- ‚ö†Ô∏è Backup plan: Additional study if needed

**Deliverable:** FDA clearance letter

---

#### M3.3: Commercial Launch Prep ‚è∞ 6 months (parallel)
- [ ] Hire sales team (5 AEs - Account Executives)
- [ ] Marketing campaigns ($1.5M budget)
  - Healthcare conferences (HIMSS, ATA)
  - Digital ads (Google, LinkedIn)
  - Content marketing (blog, whitepapers)
- [ ] Customer success team (5 people)
- [ ] Partner with distributors (medical device channels)

**Deliverable:** Go-to-market engine ready

---

### Phase 3 Outcomes

**Regulatory:**
- ‚úÖ FDA 510(k) clearance ‚Üê **GAME CHANGER**
- ‚úÖ Reimbursement codes (CPT/HCPCS)

**Business:**
- ‚úÖ 100+ paying customers
- ‚úÖ $5M ARR
- ‚úÖ 40%+ gross margins

**Valuation:** $150M-$300M (post-FDA)

---

## üöÄ Phase 4: Scale & Growth (Year 2-5)

**Goal:** Achieve unicorn status ($1B+ valuation)

**Funding:** Series B ($50M+), Series C ($100M+)

### Milestones

#### M4.1: Market Expansion ‚è∞ Year 2
- [ ] Launch in 3 verticals:
  - **Healthcare:** Hospitals, clinics (primary)
  - **Elderly care:** Nursing homes, assisted living
  - **Industrial:** Safety monitoring (secondary)
- [ ] Expand to 5 countries:
  - USA (primary)
  - Canada, UK, Germany, Australia
- [ ] Regulatory approvals: CE mark (Europe), PMDA (Japan)

**Target:** $50M ARR

---

#### M4.2: Product Evolution ‚è∞ Year 3
- [ ] WiFi 6E/7 support (better penetration)
- [ ] AI-powered predictive analytics
- [ ] Integration with EHR systems (Epic, Cerner)
- [ ] API for 3rd-party developers
- [ ] Multi-patient monitoring (up to 10 simultaneously)

**Target:** $120M ARR

---

#### M4.3: Medicare/Medicaid Integration ‚è∞ Year 4
- [ ] RPM (Remote Patient Monitoring) reimbursement
  - Medicare: $65-$150 per patient per month
  - Target: 10,000 patients
- [ ] Value-based care contracts
- [ ] ACO (Accountable Care Organization) partnerships

**Target:** $300M ARR

---

#### M4.4: Unicorn Achievement ‚è∞ Year 5-7
- [ ] $500M ARR achieved
- [ ] 70,000+ customers
- [ ] International expansion (10+ countries)
- [ ] Market leadership in WiFi sensing

**Valuation:** $5B-$10B (10-20x ARR)

**Exit options:**
- IPO (NASDAQ or NYSE)
- Strategic acquisition (Philips, GE Healthcare, Apple)
- Remain private (cash flow positive)

---

## üéØ Key Risks & Mitigation

### Technical Risks

| Risk | Impact | Probability | Mitigation |
|------|--------|-------------|------------|
| **ESP32 CSI fails** | üî¥ Critical | 30% | Pivot to camera-only, Intel 5300 NIC alternative |
| **Through-wall limited** | üü° High | 40% | Market as "single-wall" device, focus on residential |
| **Accuracy below 85%** | üü° High | 30% | Improve algorithms, collect more data, hybrid approach |

### Regulatory Risks

| Risk | Impact | Probability | Mitigation |
|------|--------|-------------|------------|
| **FDA delays** | üü° High | 50% | Pre-Sub meeting, expert consultants, buffer 6 months |
| **510(k) rejection** | üî¥ Critical | 20% | Strong predicate, excellent clinical data, backup study |
| **New regulation** | üü° Medium | 10% | Monitor regulatory changes, adapt quickly |

### Market Risks

| Risk | Impact | Probability | Mitigation |
|------|--------|-------------|------------|
| **Big Tech entry** | üî¥ Critical | 40% | Speed to market, FDA moat, B2B focus (not consumer) |
| **Reimbursement denial** | üü° High | 30% | FDA clearance first, demonstrate cost savings, lobby |
| **Slow adoption** | üü° Medium | 40% | Free trials, clinical evidence, KOL endorsements |

---

## üìà Financial Projections

### Revenue Forecast (Conservative)

| Year | ARR | Customers | CAGR |
|------|-----|-----------|------|
| **Y0 (Now)** | $0 | 0 | - |
| **Y1 (2026)** | $1M | 100 | - |
| **Y2 (2027)** | $10M | 1,000 | 900% |
| **Y3 (2028)** | $50M | 5,000 | 400% |
| **Y4 (2029)** | $150M | 15,000 | 200% |
| **Y5 (2030)** | $500M | 50,000 | 233% |

### Funding Strategy

| Round | Amount | Valuation (Post) | Dilution | Use of Funds |
|-------|--------|------------------|----------|--------------|
| **Pre-Seed** | $250K | $2.5M | 10% | MVP, grants |
| **Seed** | $5M | $20M | 25% | Clinical study, FDA prep |
| **Series A** | $20M | $100M | 20% | FDA submission, manufacturing |
| **Series B** | $50M | $500M | 10% | Scale, international expansion |
| **Series C** | $100M | $2B | 5% | Unicorn scale, M&A |

**Total dilution:** ~70% (founders retain 30%)

**Founder equity at exit ($5B valuation):** $1.5B ü¶Ñ

---

## üéØ Success Metrics

### Product KPIs

- **Accuracy:** HR <5 BPM error, RR <2 breaths/min error
- **Uptime:** 99.5%+ monitoring reliability
- **Latency:** <2 second vital signs refresh
- **Range:** 5+ meter effective distance
- **Penetration:** 30+ cm drywall

### Business KPIs

- **ARR Growth:** 200%+ YoY
- **Gross Margin:** 80%+ (SaaS), 60%+ (Hardware)
- **Customer Acquisition Cost (CAC):** <$5K
- **Lifetime Value (LTV):** >$50K
- **LTV/CAC Ratio:** >10x
- **Net Revenue Retention:** 120%+

### Regulatory KPIs

- **FDA Clearance:** Year 2-3
- **Clinical Study:** Complete by Year 2
- **ISO Certification:** Year 2
- **International Approvals:** Year 3-4

---

## üö¶ Go/No-Go Decision Points

### Decision Point 1: ESP32 Validation (Week 2)
**GO if:** SNR >10 dB, penetration >20 cm
**NO-GO if:** SNR <5 dB ‚Üí **PIVOT to camera-only**

### Decision Point 2: Pre-Seed Fundraising (Month 6)
**GO if:** $100K+ raised OR SBIR grant awarded
**NO-GO if:** Can't raise ‚Üí **Bootstrap or pause**

### Decision Point 3: Clinical Study (Month 18)
**GO if:** Accuracy >85% vs clinical devices
**NO-GO if:** Accuracy <70% ‚Üí **Re-design or pivot**

### Decision Point 4: FDA Submission (Month 24)
**GO if:** Pre-Sub positive feedback
**NO-GO if:** FDA raises major concerns ‚Üí **Delay or pivot**

---

## üìû Stakeholder Communication

### Monthly Updates

**Investors:** Progress on milestones, burn rate, runway
**Team:** Sprint goals, blockers, celebrations
**Advisors:** Technical challenges, strategic decisions
**Partners:** Collaboration opportunities, integration status

### Quarterly Board Meetings

- Financial review (P&L, cash flow, runway)
- Product roadmap updates
- Hiring plan and team health
- Fundraising strategy

---

## üìù Next Immediate Actions (30 days)

1. **Week 1:**
   - ‚úÖ Buy ESP32-S3 hardware ($30)
   - ‚úÖ Review ESP32_VALIDATION_GUIDE.md
   - ‚úÖ Setup ESP-IDF environment

2. **Week 2:**
   - üî¥ Complete ESP32 CSI validation (Issue #1)
   - üü° GO/NO-GO decision on WiFi CSI

3. **Week 3:**
   - üìπ Create demo video (Issue #2)
   - üß™ Setup testing infrastructure (Issue #3)

4. **Week 4:**
   - üíº Prepare pitch deck for Pre-Seed
   - üéØ Apply to SBIR/STTR grants
   - ü§ù Reach out to university partnerships

---

**Last updated:** October 26, 2025
**Next review:** November 26, 2025 (after ESP32 validation)

**Status:** üü° Prototype ‚Üí MVP transition in progress

**Path to Unicorn:** **VALIDATED** ‚úÖ (if ESP32 succeeds)
